GHENT, Belgium, 13 January 2014 – Ablynx [Euronext Brussels: ABLX] today announced that it will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday 16 January 2014, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
Dr Edwin Moses, CEO of Ablynx, will give a corporate presentation that will include an update on the Company’s anti-vWF Nanobody, caplacizumab, to treat acquired thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. Some improvement in recruitment has been seen since amending the clinical protocol in September 2013; nevertheless, Ablynx has decided to stop recruitment of the trial now to allow earlier analysis of the data for potential proof-of-concept. Phase II data are now expected during the first half of 2014 and if the results are promising, a Phase III study is anticipated to commence in 2015.
The slides may be accessed via the Company’s website, www.ablynx.com, under the ‘News and Events>upcoming events’ section.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact:
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m:+44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
@AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx@consilium-comms.com
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Help employers find you! Check out all the jobs and post your resume.
